Systemic immunoglobulin light chain amyloidosis

G Merlini, A Dispenzieri, V Sanchorawala… - Nature reviews Disease …, 2018 - nature.com
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by
the conversion of immunoglobulin light chains from their soluble functional states into highly …

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

M Gavriatopoulou, P Musto, J Caers, G Merlini… - Leukemia, 2018 - nature.com
The introduction of novel agents in the management of multiple myeloma and related
plasma cell dyscrasias has changed our treatment approaches and subsequently the …

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

P Garcia-Pavia, C Rapezzi, Y Adler, M Arad… - European heart …, 2021 - academic.oup.com
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D …

P Garcia‐Pavia, C Rapezzi, Y Adler… - European journal of …, 2021 - Wiley Online Library
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Molecular mechanisms of cardiac amyloidosis

Y Saito, K Nakamura, H Ito - International journal of molecular sciences, 2021 - mdpi.com
Cardiac involvement has a profound effect on the prognosis of patients with systemic
amyloidosis. Therapeutic methods for suppressing the production of causative proteins have …

[HTML][HTML] Light chain amyloidosis

P Milani, G Merlini, G Palladini - Mediterranean journal of …, 2018 - ncbi.nlm.nih.gov
Light chain (AL) amyloidosis is caused by a usually small plasma-cell clone that is able to
produce the amyloidogenic light chains. They are able to misfold and aggregate, deposit in …

Systemic AL amyloidosis: current approaches to diagnosis and management

D Fotiou, MA Dimopoulos, E Kastritis - Hemasphere, 2020 - journals.lww.com
AL amyloidosis is characterized by a low-level expansion of an indolent, small plasma cell
clone that produces amyloidogenic light chains. Amyloid aggregates or preceding …

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis

KW Zhang, KE Stockerl-Goldstein… - JACC: Basic to …, 2019 - jacc.org
Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of
misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue …

Antibodies gone bad–the molecular mechanism of light chain amyloidosis

RM Absmeier, GJ Rottenaicher, HL Svilenov… - The FEBS …, 2023 - Wiley Online Library
Light chain amyloidosis (AL) is a systemic disease in which abnormally proliferating plasma
cells secrete large amounts of mutated antibody light chains (LCs) that eventually form …

Use of novel therapies in the treatment of light chain amyloidosis

C Varga, SE Titus, D Toskic, RL Comenzo - Blood Reviews, 2019 - Elsevier
Immunoglobulin light-chain (AL) amyloidosis is a rare life-threatening disease caused by
light chains that are toxic to vital organs such as the heart, kidneys, liver and peripheral …